With increased revenues of 23 percent in the fourth quarter, Genzyme Corp. exceeded analyst expectations, ending the year with two major acquisitions under its belt and an FDA approval for Clolar. (BioWorld Today)

While Genentech Inc. logged a 43 percent jump in total product sales for 2004, analysts scrutinized the company's sales of Avastin, calling them modest and lethargic at best. (BioWorld Today)

Providing new hope for breast cancer patients, Abraxane soon will offer the antitumor benefits, without the toxic solvent side effects, of paclitaxel. (BioWorld Today)

Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for Ventavis, an inhaled product in-licensed from Schering AG in October 2003. (BioWorld Today)